An Open Label, Multicenter Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Latest Information Update: 27 Mar 2025
At a glance
- Drugs Foralumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TILS-022
- Sponsors Tiziana Life Sciences
- 27 Mar 2025 New trial record